Immunome, Inc. (IMNM)
NASDAQ:IMNM
Want to see IMNM full AI Analyst Report?
IMNM Stock Chart & Stats
$24.63
-$0.28(-2.60%)
At close: 4:00 PM EST
$24.63
-$0.28(-2.60%)
Day’s Range― - ―
52-Week Range$7.96 - $27.65
Previous CloseN/A
Volume79.27K
Average Volume (3M)1.09M
Market Cap
$2.10B
Enterprise Value$1.51B
Total Cash (Recent Filing)$582.69M
Total Debt (Recent Filing)$3.69M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Aug 19, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.39
Shares Outstanding113,250,400
10 Day Avg. Volume1,261,200
30 Day Avg. Volume1,088,415
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.96
Price to Sales (P/S)270.32
P/FCF Ratio-9.35
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue375.55
Enterprise Value/Gross Profit-32.32
Enterprise Value/Ebitda-6.46
Forecast
1Y Price Target
$35.50Price Target Upside44.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.14
Revenue Forecast (FY)$2.51M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthVery low financial leverage provides durable solvency cushion, enabling the company to withstand clinical setbacks without immediate default risk. This structural balance-sheet strength supports continued R&D and partnership negotiations, though long-term durability depends on managing cash burn to avoid dilution.
Proprietary Antibody Discovery PlatformOwning an antibody-discovery platform and a focused oncology pipeline is a sustainable competitive advantage: it can generate multiple novel targets and assets, support differentiated drug candidates, and create recurring partnership opportunities that extend value beyond single programs.
Collaboration & Licensing Revenue ModelA business model built on collaborations and licensing provides structural, non-dilutive funding avenues through upfronts, R&D funding and milestone streams. Over months this model can de-risk cash needs if the company consistently advances partnerable assets into licensing milestones.
Bears Say
Heavy Operating Cash BurnPersistently large negative operating and free cash flow indicate the company consumes capital rapidly to sustain development programs. Over a multi-month horizon this elevates refinancing and dilution risk, may force program slowdowns, and reduces flexibility to pursue optional strategic initiatives.
Material Revenue DeclineA sharp multi-year revenue decline reduces the firm's ability to internally fund R&D and increases dependence on external financing or partnerships. This structural weakening of top-line cash sources undermines sustainability of current expense levels and raises execution risk for commercial or collaborative programs.
Large Net Losses & Negative MarginsDeep net losses and negative gross profit point to a persistent mismatch between costs and revenue generation. Without meaningful revenue growth or sustained cost reductions, achieving positive margins seems remote, pressuring cash reserves and likely necessitating further financing or strategic reprioritization.
Immunome News
IMNM FAQ
What was Immunome, Inc.’s price range in the past 12 months?
Immunome, Inc. lowest stock price was $7.96 and its highest was $27.65 in the past 12 months.
What is Immunome, Inc.’s market cap?
Immunome, Inc.’s market cap is $2.10B.
When is Immunome, Inc.’s upcoming earnings report date?
Immunome, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 71 days.
How were Immunome, Inc.’s earnings last quarter?
Immunome, Inc. released its earnings results on May 12, 2026. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.556 by $0.076.
Is Immunome, Inc. overvalued?
According to Wall Street analysts Immunome, Inc.’s price is currently Undervalued.
Does Immunome, Inc. pay dividends?
Immunome, Inc. does not currently pay dividends.
What is Immunome, Inc.’s EPS estimate?
Immunome, Inc.’s EPS estimate is -0.52.
How many shares outstanding does Immunome, Inc. have?
Immunome, Inc. has 113,250,400 shares outstanding.
What happened to Immunome, Inc.’s price movement after its last earnings report?
Immunome, Inc. reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.556. Following the earnings report the stock price went down -2.16%.
Which hedge fund is a major shareholder of Immunome, Inc.?
Currently, no hedge funds are holding shares in IMNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunome Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.50 (44.13% Upside)
$35.50 (44.13% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 490.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $687.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 8.4%
Last 30 Days ▲ 8.4%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
103.72%
12-Months-Change
Fundamentals
Return on Equity
-51.15%
Trailing 12-Months
Asset Growth
80.86%
Trailing 12-Months
Company Description
Immunome, Inc.
Immunome, Inc. functions as a biopharmaceutical company dedicated to the discovery and advancement of antibody-based therapies for both cancer and infectious illnesses. A pivotal project in its oncology portfolio is IMM-ONC-01, which is engineered to target the IL-38 immune checkpoint – a protein originating from tumors that enables cancer cells to bypass the body's immune surveillance. Additionally, the company is developing IMM-BCP-01, an experimental antibody cocktail designed for the management of SARS-CoV-2 infections and COVID-19. This enterprise was founded in 2006 and its principal operations are based in Exton, Pennsylvania.
IMNM Stock 12 Month Forecast
Average Price Target
$35.50
▲(44.13% Upside)
Technical Analysis
Ownership Overview
4.75% Insiders
35.72% Mutual Funds
42.23% Other Institutional Investors
4.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---